BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5
228 results:

  • 1. HER2-low and Overexpression in Mucinous Ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
    Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
    Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The relationship between DNA mismatch repair gene and other prognostic parameters in pancreatic adenocarcinoma.
    Urganci N; Kepil N; Ergun S; Bakkaloglu OK
    J Surg Oncol; 2024 Apr; 129(5):876-884. PubMed ID: 38173349
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Divergent Malignant Melanocytic Differentiation in Ovarian Endometrioid Adenocarcinoma With Aberrant β-Catenin Expression: A Case Expanding the Histologic Spectrum of β-Catenin Activated Gynecologic Neoplasia.
    Xu J; Weisman PS
    Int J Gynecol Pathol; 2024 May; 43(3):302-307. PubMed ID: 37922945
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Association of Glycated Hemoglobin With a Risk of Pancreatic cancer in High-Risk Individuals Based on Genetic and Family History.
    Wu BU; Chen Q; Moon BH; Lustigova E; Nielsen EG; Alvarado M; Ahmed SA
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00650. PubMed ID: 37800692
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian cancer.
    Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
    Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
    Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
    Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
    Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
    Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian cancer.
    Olmez F; Oglak SC; Akgol S; Olmez OF; Bilici A; Akbayir O; Ozkose ZG; Can E; Unal O; Sirinoglu HA
    J Coll Physicians Surg Pak; 2023 Jun; 33(6):666-672. PubMed ID: 37300263
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic cancer Surveillance.
    Katona BW; Klute K; Brand RE; Everett JN; Farrell JJ; Hawthorne K; Kaul V; Kupfer SS; Paiella S; Simeone DM; Sussman DA; Zogopoulos G; Lucas AL; Kastrinos F;
    Cancer Prev Res (Phila); 2023 Jun; 16(6):343-352. PubMed ID: 37259800
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Risk of Syndrome-Associated cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.
    Chen X; Meyer MA; Kemppainen JL; Horibe M; Chandra S; Majumder S; Petersen GM; Rabe KG
    JAMA Oncol; 2023 Jul; 9(7):955-961. PubMed ID: 37200008
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Mismatch repair protein deficiency in endometriosis: Precursor of endometriosis-associated ovarian cancer in women with lynch syndrome.
    Yamaguchi M; Mikami Y; Kusunoki M; Yoshimura S; Motohara T; Kondoh E
    Taiwan J Obstet Gynecol; 2023 May; 62(3):448-452. PubMed ID: 37188452
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. High-grade serous ovarian carcinoma with a sertoliform pattern associated with BRCA mutation: a clinicopathological and molecular analysis.
    Travaglino A; Santoro A; Arciuolo D; Raffone A; Scaglione G; D'Alessandris N; Valente M; Sfregola S; Fulgione C; Onori ME; Minucci A; Zannoni GF
    Virchows Arch; 2023 Dec; 483(6):879-883. PubMed ID: 37166561
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Germline drivers of gynecologic carcinosarcomas.
    Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
    Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Characterization and digital spatial deconvolution of the immune microenvironment of intraductal oncocytic papillary neoplasms (IOPN) of the pancreas.
    Pea A; Paolino G; Martelli F; Bariani E; Piccoli P; Sereni E; Salvia R; Lawlor RT; Cheng L; Chang D; Scarpa A; Luchini C
    Virchows Arch; 2023 Aug; 483(2):157-165. PubMed ID: 37086293
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Atypical Endometriosis: Comprehensive Characterization of Clinicopathologic, Immunohistochemical, and Molecular Features.
    Wepy C; Nucci MR; Parra-Herran C
    Int J Gynecol Pathol; 2024 Jan; 43(1):70-77. PubMed ID: 37043650
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Patterns of care and outcomes of risk reducing surgery in women with pathogenic variants in non-BRCA and Lynch syndrome ovarian cancer susceptibility genes.
    Schwartz ZP; Li AJ; Walsh CS; Rimel BJ; Alvarado MM; Lentz SE; Cass I
    Gynecol Oncol; 2023 Jun; 173():1-7. PubMed ID: 37030072
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan.
    Prokofyeva DS; Mingazheva ET; Valova YV; Sakaeva DD; Faishanova RR; Nurgalieva AK; Valiev RR; Bogdanova N; Dörk T; Khusnutdinova EK
    J Ovarian Res; 2023 Apr; 16(1):66. PubMed ID: 37013556
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature.
    Chinczewski L; Feldhaus FW; Schmitt W; Braicu I; Roser E; Sehouli J
    Anticancer Res; 2023 Apr; 43(4):1655-1662. PubMed ID: 36974818
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Hereditary cancer predispositions: Comparison of multigene panel sequencing on fresh-frozen breast/ovarian tumor versus blood.
    Schwartz M; Moncoutier V; Peytral A; Le Gall J; Suybeng V; Pagès M; Masliah-Planchon J; Trabelsi-Grati O; Melaabi S; Callens C; Bièche I; Delhomelle H; De Pauw A; Saule C; Mouret-Fourme E; Gauthier-Villars M; Buecher B; Colas C; Stoppa-Lyonnet D; Golmard L
    Clin Genet; 2023 Jul; 104(1):107-113. PubMed ID: 36974006
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.